Alpha Therapeutic Corporation Names Pete DeHart as Senior Vice President, Worldwide Sales and Marketing.Business Editors & Health/Medical Writers BIOWIRE2K LOS ANGELES--(BUSINESS WIRE)--Nov. 12, 2002 Alpha Therapeutic Corporation today announced the appointment of Pete DeHart as Senior Vice President, Worldwide Sales and Marketing. In this capacity, he is responsible for all sales and marketing activities for the company's plasma derived products and the operations of its home care subsidiary Alpha Therapeutic Services. "With over 25 years of experience in the plasma products industry, Pete DeHart brings a wealth of experience to Alpha," said Edward A. Colton, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "I am pleased to welcome him back as we continue to expand our presence in the worldwide market place." Mr. DeHart previously served as Alpha's Senior Vice President, Sales and Marketing from 1990 to 2000. Most recently, he was President of ZLB Bioplasma Inc. where he helped establish that company in the United States. He previously held a variety of positions in marketing for over 12 years at Cutter Laboratories and Bayer Corporation, the successor to Cutter. He has a bachelor's degree in marketing from Weber State College and a master's degree in business administration from the University of Utah The University of Utah (also The U or the U of U or the UU), located in Salt Lake City, is the flagship public research university in the state of Utah, and one of 10 institutions that make up the Utah System of Higher Education. . "Alpha provides high quality products that improve patient care and I look forward to working with our customers to meet their needs for these important therapies," said Pete DeHart. Alpha is a leading developer of plasma derived biopharmaceutical products which are sourced, tested and manufactured in the United States. Alpha's product portfolio includes coagulation factors, immune globulin and albumin, which are distributed domestically to hospitals, pharmacies, home care companies and physicians. Internationally, Alpha's products are marketed through a network of subsidiaries, affiliates and local offices in Asia, Europe and Latin America. The raw material for Alpha's products, human blood plasma, is collected in the United States. The company owns 42 plasma collection centers strategically located across the U.S. and has a central testing laboratory in Memphis, TN, which conducts serological serological pertaining to or emanating from serology. serological test one involving examination of blood serum usually for antibody. screening tests on all plasma donations. Plasma donations are also screened for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and hepatitis C utilizing Polymerase Chain Reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ) testing. This testing is conducted by National Genetics Institute (NGI). All of Alpha's plasma derived products are manufactured at its FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. licensed fractionation fractionation /frac·tion·a·tion/ (frak?shun-a´shun) 1. in radiology, division of the total dose of radiation into small doses administered at intervals. 2. facility in Los Angeles. Over the last several years, Alpha has made a significant investment in facility upgrades, including capital improvements and enhanced compliance with current Good Manufacturing Practices (cGMPs). Alpha is committed to providing high quality, safe and cost effective therapeutics for improved patient care worldwide. Additional company information is available at www.alphather.com. |
|
|||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion